Michael R. Loebinger
Expertise in
15
conditions

Michael R. Loebinger

London, ENG, GB 
Expertise in
15
conditions
London, ENG, GB 

Overview

Michael Loebinger practices practicing medicine in London, United Kingdom.

Mr. Loebinger is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Bronchiectasis, Ciliary Dyskinesia-Bronchiectasis, Drug Induced Dyskinesia, and Situs Inversus.

He is actively involved in clinical research, co-authoring 169 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

London, ENG, United Kingdom
Other Locations
Harefield, ENG, United Kingdom
Brompton, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2x2 Factorial Randomized Open Label Trial to Determine the Clinical and Cost-effectiveness of Hypertonic Saline (HTS) 6% and Carbocisteine for Airway Clearance Versus Usual Care Over 52 Weeks in Bronchiectasis
A 2x2 Factorial Randomized Open Label Trial to Determine the Clinical and Cost-effectiveness of Hypertonic Saline (HTS) 6% and Carbocisteine for Airway Clearance Versus Usual Care Over 52 Weeks in Bronchiectasis
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drugs: Hypertonic Saline, Carbocysteine
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

169 Total Publications

The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.
The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.
Journal: American journal of respiratory and critical care medicine
Published: April 01, 2026

Frequently Asked Questions about Michael R. Loebinger

Is Michael R. Loebinger a top-rated expert for Bronchiectasis?

MediFind is an objective health platform that identifies experts based on real-world data. Michael R. Loebinger is classified as an Elite expert for Bronchiectasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael R. Loebinger participate in research or clinical trials?

Yes. Michael R. Loebinger has published 169 articles and abstracts on conditions like Bronchiectasis. You can view a list of Michael R. Loebinger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Loebinger's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile